Company intelligence / Profile preview
Verndari, Inc.
Napa, California, United Statesverndariinc.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Verndari’s VaxiPatch™ has demonstrated thermostability and higher efficacy than traditional vaccine delivery in pre-clinical studies. The company is developing a rapid-response, room-temperature-stable single-dose vaccination kit that does not require needles or refrigeration.[1][4] Their technology aims to simplify administration and improve global access to vaccines.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Vaccines (including mRNA vaccines)Intradermal microarray delivery technology[1][2][5]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Biomedical Advanced Research and Development Authority (BARDA) [5]
Beyond the preview
Go deeper on Verndari, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Verndari, Inc..